Vu Truong, Aridis Pharmaceuticals CEO (Aridis/Nasdaq)

Aridis' mon­o­clon­al an­ti­body fails PhI­II, but plans for sec­ond tri­al any­way

Aridis Phar­ma­ceu­ti­cals’ mon­o­clon­al an­ti­body missed the bar in a Phase III test in ven­ti­la­tor-as­so­ci­at­ed pneu­mo­nia caused by the gram-pos­i­tive bac­te­ria S. au­reus, the com­pa­ny an­nounced Wednes­day. 

But Aridis is plan­ning for a sec­ond Phase III study any­way once it dis­cuss­es the find­ings with the FDA and the Eu­ro­pean Med­i­cines Agency. Ex­ecs blamed re­cruit­ment chal­lenges stem­ming from Covid-19 and Rus­sia’s in­va­sion of Ukraine for the miss, cut­ting their en­roll­ment tar­get in half.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.